1. Home
  2. HRMY vs BAK Comparison

HRMY vs BAK Comparison

Compare HRMY & BAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$27.73

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo Braskem SA ADR

BAK

Braskem SA ADR

HOLD

Current Price

$4.08

Market Cap

1.4B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
HRMY
BAK
Founded
2017
1972
Country
United States
Brazil
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Chemicals
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.4B
IPO Year
2020
2002

Fundamental Metrics

Financial Performance
Metric
HRMY
BAK
Price
$27.73
$4.08
Analyst Decision
Buy
Hold
Analyst Count
10
2
Target Price
$46.70
$4.40
AVG Volume (30 Days)
900.4K
2.9M
Earning Date
05-05-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
7.97
N/A
EPS
2.71
N/A
Revenue
$868,453,000.00
N/A
Revenue This Year
$19.87
N/A
Revenue Next Year
$12.49
$5.40
P/E Ratio
$10.22
N/A
Revenue Growth
21.51
N/A
52 Week Low
$25.52
$2.32
52 Week High
$40.87
$5.30

Technical Indicators

Market Signals
Indicator
HRMY
BAK
Relative Strength Index (RSI) 32.88 47.83
Support Level $25.71 $3.34
Resistance Level $28.99 $5.30
Average True Range (ATR) 0.75 0.42
MACD 0.22 -0.08
Stochastic Oscillator 26.60 23.49

Price Performance

Historical Comparison
HRMY
BAK

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About BAK Braskem SA ADR

Braskem SA manufactures and sells chemicals, petrochemicals, fuels, and utilities. The company's geographical segments include Brazil; the United States and Europe and Mexico. It derives a majority of its revenue from Brazil. It produces olefins, such as ethylene, polymer and chemical-grade propylene, butadiene, and butene-1; fuels, such as automotive gasoline, liquefied petroleum gas, or LPG, ethyl tertiary-butyl ether, or ETBE, and methyl tertiary-butyl ether, or MTBE; intermediates, such as cumene and others.

Share on Social Networks: